Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 03, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Participate in April Investor Conferences

aTyr Pharma to Participate in April Investor Conferences
March 26, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
March 13, 2025 16:01 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
March 12, 2025 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine

aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
March 06, 2025 16:02 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
March 04, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
February 24, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
January 29, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025...
December 17, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 12, 2024 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

Next Page keyboard_arrow_right